20,724 Shares in Intersect ENT, Inc. (NASDAQ:XENT) Purchased by SG Americas Securities LLC

SG Americas Securities LLC bought a new stake in Intersect ENT, Inc. (NASDAQ:XENTGet Rating) in the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 20,724 shares of the medical equipment provider’s stock, valued at approximately $580,000. SG Americas Securities LLC owned approximately 0.06% of Intersect ENT at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of XENT. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Intersect ENT by 110.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,278 shares of the medical equipment provider’s stock valued at $117,000 after acquiring an additional 2,246 shares in the last quarter. Diametric Capital LP acquired a new position in Intersect ENT in the 4th quarter valued at about $232,000. Wolverine Asset Management LLC grew its position in shares of Intersect ENT by 6.6% during the fourth quarter. Wolverine Asset Management LLC now owns 8,850 shares of the medical equipment provider’s stock worth $241,000 after buying an additional 550 shares in the last quarter. BTG Pactual Global Asset Management Ltd acquired a new position in shares of Intersect ENT during the fourth quarter worth about $321,000. Finally, Walleye Capital LLC acquired a new position in shares of Intersect ENT during the fourth quarter worth about $601,000. 92.47% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Intersect ENT in a research report on Thursday, July 28th. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating and four have given a hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $28.27.

Intersect ENT Price Performance

XENT stock opened at $28.24 on Thursday. The business has a 50 day moving average price of $28.24 and a 200 day moving average price of $27.86. The stock has a market cap of $954.91 million, a price-to-earnings ratio of -5.90 and a beta of 1.45. Intersect ENT, Inc. has a fifty-two week low of $15.92 and a fifty-two week high of $28.25. The company has a quick ratio of 1.50, a current ratio of 1.88 and a debt-to-equity ratio of 6.89.

Intersect ENT Company Profile

(Get Rating)

Intersect ENT, Inc operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

See Also

Want to see what other hedge funds are holding XENT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intersect ENT, Inc. (NASDAQ:XENTGet Rating).

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.